Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Meningococcal group B vaccine - Pfizer

Drug Profile

Meningococcal group B vaccine - Pfizer

Alternative Names: Bivalent recombinant LP2086; Bivalent recombinant meningococcal B vaccine - Pfizer; Bivalent rLP2086; Meningococcal B rLP2086 vaccine - Pfizer; MnB-rLP2086; PF-05212366; PF-5212366; Recombinant-LP2086; rLp-2086; rLP2086; TRUMENBA

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Wyeth
  • Developer Pfizer
  • Class Meningococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Meningococcal group B infections

Most Recent Events

  • 23 Apr 2018 Meningococcal group B vaccine - Pfizer receives Breakthrough Therapy status for Meningococcal group B infections (In infants, In children) in USA
  • 06 Mar 2018 Launched for Meningococcal group B infections (In adolescents, In children, Prevention, In adults) in Canada (IM)
  • 01 Jan 2018 Pfizer completes a phase III trial for Meningococcal group B infections (In adolescents, In children, Prevention, In adults) in USA, Czech Republic, Denmark, Finland, Germany, Sweden, and Poland (IM) (NCT01543087) (EudraCT2011-005697-31)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top